Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Altimmune, Inc. (ALT)

Altimmune names Richard Menziuso as Global Controller and principal accounting officer

Neutral Impact 2 of 5 leadership Written later

Altimmune appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. CFO Gregory Weaver remains in his role, so the change is limited to the company's accounting leadership.

Key points

  • Appointment made by the Board on September 24, 2026, effective September 29, 2026
  • Menziuso has 28 years of finance and accounting experience, including 12 years in public accounting
  • Previously Vice President, Corporate Controller at Centessa Pharmaceuticals from 2021 until its 2026 acquisition by Eli Lilly
  • Gregory Weaver will remain Chief Financial Officer

The filing

CompanyAltimmune, Inc. (ALT)
Form8-K, current report
Filed with the SECSep 29, 2026, 7:03 AM ET
Accession number0001326190-26-000056

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.